8-K
filed November 2, 2022, 7:59 PM ET
ticker CSTL
CIK 0001447362
earnings
confidence high
sentiment positive
materiality 0.80
Castle Biosciences Q3 revenue $37M (+58% YoY), raises 2022 guidance to $132-137M
CASTLE BIOSCIENCES INC
2022-Q3 EPS reported
-$1.79
revenue$98,701,000
- Q3 revenue $37.0M (+58% YoY); total test reports 12,114 (+57% YoY).
- Net loss $(20.2)M vs $(11.8)M; adjusted EBITDA $(8.3)M vs $(5.5)M.
- 2022 revenue guidance raised to $132-137M from $130-135M.
- Three-year target: FY2025 revenue $255-330M; positive net operating cash flow by 2025.
- Acquisitions TissueCypher (690 reports) and IDgenetix (1,208 reports) contributed in Q3.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
CASTLE BIOSCIENCES INC reported the third quarter ended September 30, 2022 results: revenue $37.0 million, net income $(20.2) million. Guidance raised.
- Period
- the third quarter ended September 30, 2022
- Revenue
- $37.0 million
- Net income
- $(20.2) million
- Guidance
- raised
- Result
- reported results
Exact text from the filing
Revenues were $37.0 million, a 58% increase compared to $23.5 million during the same period in 2021.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
CASTLE BIOSCIENCES INC reported the nine months ended September 30, 2022 results: revenue $98.7 million, net income $(46.5) million. Guidance raised.
- Period
- the nine months ended September 30, 2022
- Revenue
- $98.7 million
- Net income
- $(46.5) million
- Guidance
- raised
- Result
- reported results
Exact text from the filing
Revenues were $98.7 million, a 43% increase compared to $69.0 million during the same period in 2021.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.